Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) was the recipient of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 51,300 shares, an increase of 57.8% from the February 13th total of 32,500 shares. Based on an average trading volume of 66,900 shares, the short-interest ratio is currently 0.8 days. Approximately 1.3% of the shares of the stock are sold short.
Hedge Funds Weigh In On Monopar Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the business. Janus Henderson Group PLC bought a new position in shares of Monopar Therapeutics in the 4th quarter valued at $23,435,000. Adage Capital Partners GP L.L.C. bought a new position in shares of Monopar Therapeutics in the 4th quarter valued at $13,182,000. RA Capital Management L.P. bought a new position in shares of Monopar Therapeutics in the 4th quarter valued at $11,247,000. Point72 Asset Management L.P. bought a new stake in Monopar Therapeutics during the 4th quarter worth $3,694,000. Finally, ADAR1 Capital Management LLC bought a new stake in Monopar Therapeutics during the 4th quarter worth $2,861,000. Institutional investors own 1.83% of the company's stock.
Wall Street Analyst Weigh In
A number of equities analysts have commented on the company. HC Wainwright raised their price objective on Monopar Therapeutics from $22.00 to $40.00 and gave the stock a "buy" rating in a research note on Wednesday, January 22nd. Piper Sandler assumed coverage on Monopar Therapeutics in a research note on Friday, January 10th. They set an "overweight" rating and a $72.00 price objective on the stock.
Check Out Our Latest Research Report on MNPR
Monopar Therapeutics Stock Up 0.4 %
Shares of MNPR traded up $0.14 during midday trading on Tuesday, hitting $34.37. The company's stock had a trading volume of 31,272 shares, compared to its average volume of 360,284. Monopar Therapeutics has a one year low of $1.72 and a one year high of $54.30. The company's fifty day simple moving average is $36.16 and its two-hundred day simple moving average is $21.99. The stock has a market capitalization of $209.73 million, a price-to-earnings ratio of -17.45 and a beta of 1.18.
About Monopar Therapeutics
(
Get Free Report)
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
Featured Stories
Before you consider Monopar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monopar Therapeutics wasn't on the list.
While Monopar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
